Cortechs.ai | NeuroQuant ARIA

Automated quantification, visualization, and longitudinal tracking of brain lesions to support ARIA surveillance

NeuroQuant® v5 offers precise segmentation, quantification, and longitudinal tracking of both FLAIR and T2*GRE/SWI lesions. This advanced functionality offers assistance with the surveillance of amyloid-related imaging abnormalities, such as ARIA-E and ARIA-H, in patients receiving anti-amyloid therapies.

Cortechs.ai|NeuroQuant ARIA
Cortechs.ai|NeuroQuant ARIA
Cortechs.ai|NeuroQuant ARIA

A Complete Solution for Quantitative Lesion Tracking

NeuroQuant® v5 is the only clinically validated solution that detects and quantifies cerebral microbleeds and superficial siderosis on both T2*GRE and SWI scans. Coupled with FLAIR lesion quantification of cerebral edema, NeuroQuant® v5 offers a complete solution for AI-assisted monitoring of Alzheimer’s Disease patients on anti-amyloid immunotherapies.

Benefits

Cortechs.ai|NeuroQuant ARIA

Lesion quantification

Accurate segmentation and longitudinal tracking of FLAIR, T2*GRE, and SWI lesions

Cortechs.ai|NeuroQuant ARIA

OEM protocol standardization

To ensure reproducible outcomes and accuracy over time

Cortechs.ai|NeuroQuant ARIA

Longitudinal disease tracking

Monitor lesion counts and maximum diameters over time, with comparisons to baseline and prior timepoints

NeuroQuant® ARIA reports

Reports that provide quantitative insights to support physicians in tracking FLAIR and T2*GRE/SWI lesions over time compared with a baseline study.

Cortechs.ai|NeuroQuant ARIA

Understanding CPT Codes 0865T & 0866T

As of January 1, 2024, new Category III CPT codes (0865T, 0866T) are active for AI-assisted quantitative brain MRI analysis. These codes apply to a variety of vendor solutions, including Cortechs.ai, and serve as an essential step toward achieving permanent reimbursement.

Related insights

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.

02/15/2025

NeuroQuant® Dementia: Advancing Alzheimer’s Disease Care in the Era of DMTs

AI-driven brain volumetric analysis is revolutionizing Alzheimer’s care, providing precise diagnostic support, monitoring, and early detection.
Scroll to Top